| Bioactivity | O-7460 is a potent and selective DAGLα inhibitor, with an IC50 of 0.69 μM. O-7460 shows selectivity over onoacylglycerol lipase (MAGL), human CB1 and CB2 cannabinoid receptors. O-7460 can decrease HFD-caused an up-regulation of 2-AG levels[1]. |
| Target | IC50: 0.69 μM (DAGLα) |
| Invitro | O-7460 (10 μM; 20 min) decreases the Ionomycin (3 μM)-induced formation of 2-AG in N18TG2 cells[1]. |
| In Vivo | O-7460 (6-12 mg/kg; a single i.p.) induces a time- and dose-dependent decrease in high-fat diet (HFD) intake and counteracts the body weight increase of mice[1].O-7460 (12 mg/kg; i.p.) decreases the HFD-caused an up-regulation of 2-AG levels in the hypothalamus and liver of mice[1]. Animal Model: |
| Name | O-7460 |
| CAS | 1572051-31-0 |
| Formula | C25H48FO5P |
| Molar Mass | 478.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Bisogno T, et, al. A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects. Br J Pharmacol. 2013 Jun;169(4):784-93. |